Free tool
FAERS Monitor: Osenvelt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761404 or its brand name (Osenvelt, Denosumab-Bmwo). Reports on generic versions are filed under their own applications.
Reports
33
Serious
25
76% of reports
Hospitalization
6
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- arthralgia5
- back pain4
- chills4
- diarrhoea4
- vomiting4
- abdominal pain upper3
- death3
- drug ineffective3
- fatigue3
- headache3
- pain in extremity3
- peripheral swelling3
- bone pain2
- dizziness2
- dyspepsia2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 30 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,126 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bone pain | 2 | 21.8 | 5.7 | 22 |
| chillsSignal | 4 | 21.7 | 8.7 | 60 |
| dyspepsia | 2 | 13.0 | 3.4 | 12 |
| peripheral swellingSignal | 3 | 12.4 | 4.2 | 21 |
| back painSignal | 4 | 11.0 | 4.4 | 27 |
| abdominal pain upperSignal | 3 | 9.3 | 3.2 | 15 |
| arthralgiaSignal | 5 | 7.7 | 3.4 | 23 |
| pain in extremitySignal | 3 | 6.5 | 2.2 | 9 |
| vomitingSignal | 4 | 5.4 | 2.2 | 11 |
| diarrhoeaSignal | 4 | 3.9 | 1.6 | 6 |
| headache | 3 | 3.0 | 1.0 | 2 |
| dizziness | 2 | 2.6 | 0.7 | 1 |
| fatigue | 3 | 2.5 | 0.8 | 1 |
| death | 3 | 2.2 | 0.8 | 1 |
| drug ineffective | 3 | 1.5 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.